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HTLV-1 causes adult T-cell leukemia (ATL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Recombinant envelope glycoprotein is used in production of diagnostic enzyme-linked immunosorbent assay (ELISA) kit. There
are some reports that a signiﬁcant percentage of Iranian HTLV-1 infected patients showed no seroreactivity with MTA-1 peptide,
while HTLV-1 had been conﬁrmed by PCR detection methods or ELISA kits containing a cocktail of HTLV-1 speciﬁc peptides.
This report describes experiments designed to determine whether some discrepancies between ELISA and PCR results could be
duetotruncationofimmunodominantepitopesusingimmunoassaymethod.WehaveclonedtheMTA-1epitopeofenvgenefrom
HTLV-1 in NotI/NdeI sites of pET22b(+) expression vector. Sequencing analysis of recombinant plasmids revealed an insertion
of a cytosine in position 271 causing a stop codon in the MTA-1 protein translation. SDS-PAGE analysis also failed to reveal the
presence of the desired protein. Subjects with a mutant HTLV-1 env gene were shown to be seronegative using ELISA, but positive
with PCR.
Copyright © 2008 Mohammad Reza Abbaszadegan et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Infection with human T-cell lymphotropic virus type-1
(HTLV-1) is a growing medical problem, with over 20
million estimated infections worldwide [1]. HTLV-1 has
been identiﬁed as the etiologic agent of two distinct human
diseases: adult T-cell leukemia (ATL) and a chronic, progres-
sive demyelinating disorder known as HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) [2].
The virus has also been associated with a number of
autoimmune diseases, including Sj¨ ogren’s syndrome, uveitis,
and an inﬂammatory arthropathy [3]. The regions of HTLV-
1 endemicity, with proportionately higher rates of infection,
are clustered in southern Japan, the Caribbean, South
America, the southern United States, equatorial Africa, and
northeastern Iran [4, 5]. Three major routes of HTLV-1
transmission are mother to child via breast milk, sexual
intercourse, and blood transfusion [6, 7]. Otherwise, HTLV-
1 is not easily transmissible, since cell-to-cell contact is pre-
sumably required [6, 8]. Retroviruses can employ a variety
of diﬀerent cell surface proteins as receptors for binding
and entry into host cells. Entry involves an interaction
between the surface protein (SU) of the virus envelope
glycoprotein (env) and the cellular receptor with subsequent
fusion of the cellular and viral membranes mediated by the
transmembrane (TM) region of env [9, 10]. According to
current diagnostic criteria, immunoreactivity with p24 and
one of the envelope proteins (usually gp46) is considered
diagnostic of HTLV-I or HTLV-II infection; however, this
immunoreactivity pattern still resultsin a signiﬁcant propor-
tion of false negative. MTA-1 peptide from the HTLV-1 gp46
region demonstrated the highest percentage of reactivity
with HTLV-I positive sera, particularly among subjects of
Japanese ancestry [11, 12]. There are some reports that2 Journal of Biomedicine and Biotechnology
a higher percentage of Iranian HTLV-1 infected patients
showed no seroreactivity with MTA-1 peptide, while HTLV-
1 infection of patients had been conﬁrmed by PCR detection
methods or ELISA kits containing a cocktail of HTLV-1
speciﬁc peptides [4].
Some of these discrepancies could be explained by
variation in immune response at diﬀerent population. The
other cases may be as a result of truncation of gp46 region
in HTLV subtybes. Previously, it has been demonstrated that
point mutations or deletion of glycosylation sites can result
in a nonfunctional env protein [13].
This report describes experiments designed to determine
whether some discrepancies between ELISA and PCR results
could be due to truncation of immunodominant epitopes
using immunoassay method.
2. MATERIALS AND METHODS
To prepare MTA-1 insert DNA, primers were chosen based
on their locations within the prototype HTLV-1 genomic
sequence available in the Gen-Bank database with accession
number AF.33817. In order to put sticky end into blunt-
ended ampliﬁed molecule, the sequences of restriction
enzymes Nde I and Not I were incorporated into the 5  ends
of forward and reverse primers, respectively, with regard to
cloning site of pET-22b(+) vector (Novagen, Madison, WI,
USA), and restriction sites ﬂanked by 3 spacer nucleotides
at the 5  end to allow for eﬃcient digestion. The PCR
ampliﬁcationofDNAfragmentofinterestwasperformedfor
35 cycles at the following temperatures: 10 cycles; 1minute
at 94◦C, 45seconds at 55◦C, 2 minutes at 72◦C, and 25
cycles; 45seconds at 94◦C, 1minute at 65◦C and 2minutes at
72◦C with a ﬁnal extension of 20minutes at 72◦C in a DNA
thermal cycler (Perkin-Elmer 480). Final composition of the
reaction was 100ng of pool of four DNA samples, 20pmole
appropriate primers, 1.5mM dNTP mixture, and one unit
(u) of Pfu DNA polymerase in the buﬀer containing MgSO4
in 25µl reaction volume. Sequences of the primers were as
follows.
Forward primer: 5 -GCGCATATGGCTCCAGGATAT-
GACCCCATC-3 .
Reverse primer: 5 -ATAGCGGCCGCGGAGCGGGAT-
CCTAGGGTG-3 .
Expected product size of 455bp fragment was ampliﬁed,
gel puriﬁed using CoreOne gel extraction kit. Ampliﬁed
DNA insert was sequentially digested and followed by a
second gel puriﬁcation.
Double digestion of plasmid DNA (5493bp) was per-
formed using NotI and NdeI restriction enzymes at 37◦C,
overnight. After puriﬁcation, cut plasmid DNA was dephos-
phorylated with calf intestine phosphatase enzyme. The
modiﬁed and digested pET-22b(+) plasmid was gel puriﬁed
prior to ligation with the insert.
The appropriate amount of insert used in the ligation
assay was calculated using the following equation: [(amount
of vector, ng) × (size of insert, kb)/(size of vector, kb) ×
(molar ratio of insert/vector)] = ng of insert DNA. pET-
22b(+)/MTA-1 constructed by ligating MTA-1 sequence into
the pET-22b(+) expression vector via NotI–NdeI sites, and
the reactions were carried out by T4 DNA ligase enzyme in
10µl volume. T4 DNA ligase was then inactivated by heat
treatment for 20minutes at 65◦C to increase the eﬃciency
of transformation. Plasmid carrying the gene was used
to transform bacterial cells (E. coli DH5a) using Inoue
transformation method.
The cells were grown overnight at 37◦C on SOB plates
containing 50µg/mL ampicillin. Plasmid DNA was extracted
using Bioneer plasmid extraction kit (Bioneer, Korea, USA);
screening was performed using PCR colony with insert-
speciﬁc PCR primers, and restriction analysis and recombi-
nant plasmid sequenced.
For protein analysis, a recombinant pET-22b(+)/MTA-1
plasmid was transformed into expression host E. coli
BL21(DE3) strain containing a chromosomal copy of the
gene for T7 RNA polymerase. Preparation of recombinant
cells was followed by induction and optimization of expres-
sion of target protein using a range of IPTG concentration
fr o m0 .1m Mt o1m Mad d edt oagr o wi n gcul t ur e .C ell sw e r e
collected from the growth medium by centrifugation, 14000-
rpm, 1minute, at room temperature. The pelleted cells
were resuspended in extraction buﬀer (50mM potassium
phosphate, pH 7.8, 400mM NaCl, 10% Glycerol, 100mM
KCl, and 0.5% Triton X-100) and subjected to centrifugation
at 14,000rpm for 20minutes. Supernatants were removed;
250µL 2X SDS/PAGE sample buﬀer was added to cells
and equal volumes of supernatant mixed with 2X sample
buﬀer, incubated at 95◦Cf o r5 m i n u t e sa n ds u b j e c t e dt o
reducing sodium dodecyl sulfate SDS-polyacrylamide gel
electrophoresis (PAGE).
3. RESULTS AND DISCUSSION
pET-22b(+) vectors were chosen as a convenient and pow-
erful system for cloning and expression of recombinant
protein in E. coli [14]. Extraction of plasmid, digestion,
isolation, ligation, transformation, identiﬁcation, and PCR
were performed as described previously [15]. The conditions
of the ligation reactions were ﬁrst subjected to a number of
optimizations for various parameters [16]. The temperature
of 16◦C resulted in desirable result. In the experimental sets
focusing on the amount of T4 DNA ligase, both 10 and
20units of enzyme gave high eﬃciency. The time of the
ligase reaction was inﬂuential as 4-hour ligation reaction
resulted in a high number of recombinant plasmids than the
overnight ligation.
Oneofthestrategiesforhigh-eﬃciencycloningofsticky-
end DNA molecules involves dephosphorylation of vectors
with calf intestinal phosphatase (CIP), which catalyses the
hydrolysis of 5 -phosphate groups from DNA. Treatment
with CIP also increased the ligation eﬃciency of the PCR-
ampliﬁed inserts.
Using these strategies as well as the optimized ligation
conditions, three diﬀerent molar ratios of insert to vector
DNAs were tested. The ratios of 1 : 1 gave signiﬁcantly low
transformation eﬃciency, while the insert to vector ratio of
3 : 1 resulted in the highest number of transformants.
As shown in Figure 1, Lanes 2 and 4 showed digested
plasmid from transformed clones with no insert using AlwMohammad Reza Abbaszadegan et al. 3
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Figure 1: Alw 441 restriction analysis of plasmids, extracted from
transformed clones. Plasmids of transformed clones are visualized
on ethidium bromide-stained 1% agarose gel after puriﬁcation and
digestion with Alw 441. Lane 1 : 1kb DNA Ladder; Lane 2, 4:
digested plasmid from transformed clones with no insert using Alw
441 restriction enzyme; Lane 3, a transformed clone containing
pET-22b(+) with a 455bp MTA-1 insert; Lane 5 indicates Alw 441
restriction map of nonrecombinant pET-22b(+) (negative control).
TTCCAG: CCCCCCACCTGACGTTACCATTTAACTGGACCCACTGCTTTGACCCCCA
TTCCAGCCCCCCCACCTGACTTAACCATTTAACTGGACCCACGGCTTGAACCCCCA
TTCCAGCCCCCCCACCTGACKTWACCATTTAACTGGACCCACKGCTTKRACCCCCAR
 F      Q       P       P      H      L       T       ?       P       F      N      W     T       H      ?        ?       ?        P      Q
     270                    280                    290                     300                    310                    3
Figure 2: Sequencinganalysis.Aninsertionofacytosineinposition
271 causing a stop codon in the MTA-1 protein translation.
441 restriction enzyme. One of three transformed clones
(Lane 3) contained recombinant pET-22b(+) carrying a
455bp fragment. The presence of this fragment changed Alw
441 restriction map of recombinant pET-22b(+) (Figure 1,
Lane 3) in comparison with nonrecombinant pET-22b(+)
(Figure 1,L a n e5 ) .
Sequencing analysis showed an insertion of a cytosine in
position 271 causing a frame shift and stop codon in protein
translation (Gen-Bank accession no. DQ911752) (Figure 2).
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Figure 3: Ampliﬁcation of HTLV-1 MTA1-coding region. A 455bp
fragmentwasampliﬁedfromtheMTA-1regionofHTLV-1genome.
PCRproducts were electrophoresed ina 1.5% agarose gel, stained in
ethidium bromide, and photographed. Lane 1, 100bp ladder; lane
2, negative control; lane 3, PCR product from an ELISA positive
patient; Lane 4, PCR product from an ELISA negative patient.
All four DNA samples used in this study send for sequencing
and showed the same results. For further investigation, SDS-
PAGE analysis was performed to detect potential MTA-1
protein. However, this analysis failed to reveal the presence
of the desired protein band 37KDa. It is likely that the
MTA-1 truncated protein resulted from 271insC mutation is
an unstable and degradable protein giving no band in SDS-
PAGE.
Screening for HTLV-1 has become routine in blood
banks in the most developed nations. The screening pro-
cess is initiated with an HTLV-1-speciﬁc enzyme-linked
immunosorbent assay (ELISA). Samples which are found
to be repeatedly positive by ELISA are conﬁrmed through
a PCR assay or, more commonly, a commercially available
Western blot assay. The standardized ELISA assay incorpo-
rates viral proteins obtained from a number of recombinant
HTLV-1 glycoproteins, which are included to increase the
sensitivityandspeciﬁcityoftheassay.Inasigniﬁcantnumber
of cases, which can be demonstrated throughout the world,
theHTLV-1/2ELISAisnegative,butHTLV-1PCRispositive.
The causative agent(s) and medical signiﬁcance of the
HTLV-1 seroindeterminate status are unclear. A number of
potentialexplanationshavebeenprovidedforthisserological
ﬁnding, including (i) infection with a truncated or deleted
form of HTLV-1, (ii) infection with a novel retrovirus
bearing signiﬁcant homology to HTLV-1, and (iii) infection
with prototype HTLV-1 at viral loads which are below the
range of current methods of detection. Previous studies have
had limited success in addressing these possibilities.
The presence of truncated form of HTLV-1 gp46 protein
could have been implicated as potential agents of disease in4 Journal of Biomedicine and Biotechnology
a number of cases. Such truncated form of HTLV-1 could
theoretically account for an incomplete banding pattern on
an HTLV-1-Western blotting due to absence or alteration of
crucial immunodominant viral epitope.
The 271insC mutation in MTA-1 envelope genomic
sequences causing a truncated protein can explain the
seronegative (ELISA negative) HTLV-1 infected individuals
who are HTLV-1 PCR positive. Although samples found to
be repeatedly negative by HTLV-1-ELISA, HTLV-1 genomic
sequences were readily detectable by PCR in the peripheral
blood lymphocytes of these infected individuals (Figure 3).
The positive results were also conﬁrmed by sequencing.
Therefore, in addition to variation in immune response
at diﬀerent population, some of the discrepancies between
PCR detection methods and ELISA kits containing MTA-1
peptide from the HTLV-1 gp46 region could be explained by
truncation of gp46 region in HTLV subtybes. In consistent
with this notion, it has been demonstrated that point
mutations or deletion of glycosylation sites can result in a
nonfunctional env protein [13].
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